Teladoc, Inc., together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation. Its enterprise scale platform is offered for real-time sharing of clinical and non-clinical data in real time among the Teladoc constituents, which include Members, Providers, physician network operations center staff, nurses, SureScripts for electronic medication prescription writing, routing and fulfillment and health plans for claims processing, clinical summaries and clinical alerts.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Information Services
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: TDOC
- Previous Close: $21.15
- 50 Day Moving Average: $19.70
- 200 Day Moving Average: $17.98
- 52-Week Range: $9.08 - $22.05
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -27.83
- P/E Growth: -0.39
- Market Cap: $973.58M
- Outstanding Shares: 46,032,000
- Beta: 0.27
- Net Margins: -69.15%
- Return on Equity: -32.68%
- Return on Assets: -25.11%
Companies Related to Teladoc:
- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 4.50%
- Quick Ratio: 4.50%
What is Teladoc's stock symbol?
Teladoc trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
Where is Teladoc's stock going? Where will Teladoc's stock price be in 2017?
14 brokerages have issued twelve-month price targets for Teladoc's shares. Their forecasts range from $20.00 to $29.00. On average, they expect Teladoc's stock price to reach $23.31 in the next twelve months.
When will Teladoc announce their earnings?
Teladoc is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Teladoc stock?
Here are some recent quotes from research analysts about Teladoc stock:
- Cantor Fitzgerald analysts commented, "We estimate net proceeds to the company will be about $105 million. In addition, 1.6 million shares were sold by certain shareholders. With the capital raise, TDOC has put to bed any concerns that may have existed about its ability to fund near term losses, which we expect to narrow during the course of 2017. Net cash now stands at about $135 million and we expect the company to use about $20-25 million in cash in 2017. With the higher share count, our estimated loss per share declines to $0.43 from $0.50. Assuming no other changes in our DCF, our price target declines from $25 to $23 after factoring the additional share count and cash proceeds. The shares offer 35% upside to our revised target price. Our rating remains at Overweight." (1/19/2017)
According to Zacks Investment Research, "Teladoc is witnessing steady business growth with insurers and customers increasingly embracing telehealth. It’s organic growth initiative remains on track. With four acquisitions completed since its inception, the insurer has expanded its distribution capabilities and broadened its service offering. Its buyout of HealthiestYou is expected to further solidify its leadership position. Also the company boasts an impressive clientele. The company has also provided strong guidance for 2016 and 2017. It has, nevertheless, incurred significant losses in each quarter since 2013. As of Dec 31, 2015, it had an accumulated deficit of $130.5 million. These losses pertain to substantial investments made for growth. Despite its growing business, the company’s share price has underperformed the Zacks categorized Medical Services industry. " (1/11/2017)
Who owns Teladoc stock?
Teladoc's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (6.68%), Cortina Asset Management LLC (2.34%), Brown Advisory Inc. (1.32%), State Street Corp (0.83%), Davidson Kempner Capital Management LP (0.65%) and Hodges Capital Management Inc. (0.48%). Company insiders that own Teladoc stock include Adam C Vandervoort, Dana G Jr Mead, James K Outland, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael H King, Trident Capital Fund Vi Lp and William H Frist.
Who sold Teladoc stock? Who is selling Teladoc stock?
Teladoc's stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Wall Street Associates, Allianz Asset Management AG and Aberdeen Asset Management PLC UK. Company insiders that have sold Teladoc stock in the last year include Adam C Vandervoort, James K Outland, Jason N Gorevic, Lp Chp III, Mark Hirschhorn, Michael H King and Trident Capital Fund Vi Lp.
Who bought Teladoc stock? Who is buying Teladoc stock?
Teladoc's stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Cortina Asset Management LLC, Hodges Capital Management Inc., Elkfork Partners LLC, Boothbay Fund Management LLC and State Street Corp. Company insiders that have bought Teladoc stock in the last two years include Dana G Jr Mead and William H Frist.
How do I buy Teladoc stock?
Shares of Teladoc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Teladoc stock cost?
One share of Teladoc stock can currently be purchased for approximately $21.15.